Table 2 Association of tumor GFRα1, GFRα3 and SDC3 mRNA expression with clinicopathologic parameters of patients with mammary carcinoma
GFRα1 expression (n (%)) | GFRα3 expression (n (%)) | SDC3 expression (n (%)) | |||||
|---|---|---|---|---|---|---|---|
Parameter | n | mRNA | P | mRNA | P | mRNA | P |
Age (years) | |||||||
≤ 35 | 16 | 14 (87.5) | 0.005 | 11 (68.8) | 0.043 | 8 (50.0) | 0.399 |
35-55 | 92 | 45 (48.9) | 40 (43.5) | 33 (35.9) | |||
> 55 | 51 | 21 (41.2) | 17 (33.3) | 16 (31.4) | |||
Tumor size (cm) | |||||||
≤ 2 | 13 | 6(46.2) | 0.62 | 4 (30.8) | 0.406 | 7 (53.8) | 0.364 |
2 ~ 5 | 115 | 56 (48.7) | 48 (417) | 39 (33.9) | |||
> 5 | 31 | 18 (58.1) | 16 (51.6) | 11 (35.5) | |||
Histologic type | |||||||
Ductal | 150 | 78(52.0) | 0.142 | 67(44.7) | 0.127 | 54(36.0) | 0.333 |
Lobular | 6 | 2(33.3) | 1(16.7) | 1(16.7) | |||
Mucinous | 3 | 0(0) | 0(0) | 2(66.7) | |||
Lymph node metastasis | |||||||
0 | 55 | 20 (36.4) | 0.013 | 19 (34.5) | 0.235 | 23 (41.8) | 0.481 |
1 ~ 3 | 55 | 28 (50.9) | 24(43.6) | 17 (30.9) | |||
>3 | 49 | 32 (65.3) | 25 (51.0) | 17 (34.7) | |||
Grade | |||||||
I | 13 | 8 (61.5) | 0.436 | 6 (46.2) | 0.678 | 7 (53.8) | 0.124 |
II | 102 | 53 (52.0) | 41 (40.2) | 31 (30.4) | |||
III | 44 | 19 (43.2) | 21 (47.7) | 19 (43.2) | |||
Stage | |||||||
I-II | 85 | 32 (37.6) | 0.001 | 32 (37.6) | 0.162 | 31 (36.5) | 0.861 |
III-IV | 74 | 48 (64.9) | 36(48.6) | 26 (35.1) | |||
ER status ^ | |||||||
- | 94 | 49 (52.1) | 0.582 | 37 (39.4) | 0.297 | 31 (33.0) | 0.364 |
+ | 65 | 31 (47.7) | 31 (47.7) | 26 (40.0) | |||
PR status ^^ | |||||||
- | 90 | 44 (48.9) | 0.681 | 36 (40.0) | 0.421 | 27 (30.0) | 0.079 |
+ | 69 | 36 (52.2) | 32 (46.4) | 30 (43.5) | |||
HER-2 * | |||||||
- | 121 | 53 (43.8) | 0.003 | 47 (38.8) | 0.074 | 44 (36.4) | 0.809 |
+ | 38 | 27 (71.1) | 21 (55.3) | 13 (34.2) | |||